October 13, 2020 07:04 AM EDTUpdated October 15, 06:19 AM

Covid-19 roundup: Vaxart doses first patient in new clinical vaccine study; NIAID launches study to find potential therapies in repurposed drugs

California-based Vaxart has dosed the first patient in a Phase I study of its Covid-19 candidate.

The oral candidate, VXA …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Vaxart dos­es first pa­tient in new clin­i­cal vac­cine study; NI­AID launch­es study to find po­ten­tial ther­a­pies in re­pur­posed drugs